Back to Search
Start Over
Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis
- Source :
- M2 Pharma. December 4, 2017
- Publication Year :
- 2017
-
Abstract
- M2 PHARMA-December 4, 2017-Merck passes Health Canada's approval for MAVENCLAD (Cladribine Tablets) to treat relapsing-remitting multiple sclerosis (C)2017 M2 COMMUNICATIONS Healthcare company Merck reported on Friday the receipt of Health [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Pharma
- Publication Type :
- News
- Accession number :
- edsgcl.517264038